TWI229081B - 2-phenyl-substituted imidazotriazinones - Google Patents

2-phenyl-substituted imidazotriazinones Download PDF

Info

Publication number
TWI229081B
TWI229081B TW089124605A TW89124605A TWI229081B TW I229081 B TWI229081 B TW I229081B TW 089124605 A TW089124605 A TW 089124605A TW 89124605 A TW89124605 A TW 89124605A TW I229081 B TWI229081 B TW I229081B
Authority
TW
Taiwan
Prior art keywords
cns
alkyl
ministry
printed
group
Prior art date
Application number
TW089124605A
Other languages
English (en)
Chinese (zh)
Inventor
Ulrich Niewohner
Mazen Es-Sayed
Helmut Haning
Thomas Schenke
Karl-Heinz Schlemmer
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI229081(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19750085A external-priority patent/DE19750085A1/de
Priority claimed from DE1998112462 external-priority patent/DE19812462A1/de
Priority claimed from DE1998140289 external-priority patent/DE19840289A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of TWI229081B publication Critical patent/TWI229081B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW089124605A 1997-11-12 1998-11-11 2-phenyl-substituted imidazotriazinones TWI229081B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19750085A DE19750085A1 (de) 1997-11-12 1997-11-12 2-Phenyl-substituierte Imidazotriazinone
DE1998112462 DE19812462A1 (de) 1998-03-23 1998-03-23 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
DE1998140289 DE19840289A1 (de) 1998-09-04 1998-09-04 2-Phenyl-substituierte Imidazotriazinone

Publications (1)

Publication Number Publication Date
TWI229081B true TWI229081B (en) 2005-03-11

Family

ID=27217917

Family Applications (2)

Application Number Title Priority Date Filing Date
TW089124605A TWI229081B (en) 1997-11-12 1998-11-11 2-phenyl-substituted imidazotriazinones
TW087118724A TW513431B (en) 1997-11-12 1998-11-11 2-phenyl-substituted imidazotriazinones

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW087118724A TW513431B (en) 1997-11-12 1998-11-11 2-phenyl-substituted imidazotriazinones

Country Status (43)

Country Link
US (9) US6362178B1 (https=)
EP (3) EP1049695B1 (https=)
JP (2) JP3356428B2 (https=)
KR (2) KR100430355B1 (https=)
CN (2) CN1123573C (https=)
AR (2) AR013759A1 (https=)
AT (1) ATE213246T1 (https=)
AU (1) AU738675B2 (https=)
BG (1) BG65257B1 (https=)
BR (2) BR9816155B1 (https=)
CA (2) CA2395558C (https=)
CH (1) CH693954A5 (https=)
CO (1) CO4980861A1 (https=)
CU (1) CU23063A3 (https=)
CY (1) CY1112949T1 (https=)
CZ (1) CZ301911B6 (https=)
DE (3) DE59803108D1 (https=)
DK (3) DK1049695T3 (https=)
EE (1) EE04781B1 (https=)
ES (3) ES2194567B1 (https=)
FI (1) FI113772B (https=)
GB (1) GB2346877B (https=)
HN (1) HN1998000175A (https=)
HR (2) HRP20000292B1 (https=)
HU (3) HU228196B1 (https=)
ID (1) ID25871A (https=)
IL (3) IL135462A0 (https=)
IN (1) IN188419B (https=)
LU (1) LU90561B1 (https=)
MY (1) MY138535A (https=)
NO (2) NO314940B1 (https=)
NZ (1) NZ504436A (https=)
PE (1) PE131799A1 (https=)
PL (2) PL194801B1 (https=)
PT (2) PT1049695E (https=)
SE (1) SE522809C2 (https=)
SI (2) SI1049695T1 (https=)
SK (1) SK287161B6 (https=)
TR (1) TR200001338T2 (https=)
TW (2) TWI229081B (https=)
UA (1) UA46166C2 (https=)
UY (2) UY25246A1 (https=)
WO (1) WO1999024433A1 (https=)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
CA2395558C (en) * 1997-11-12 2007-07-17 Bayer Aktiengesellschaft Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
IL139457A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
CA2395418A1 (en) 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Isoxazolo pyrimidinones and the use thereof
WO2001047929A1 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Triazolotriazinone und ihre verwendung
MXPA02006240A (es) * 1999-12-24 2003-01-28 Bayer Ag Nuevas imidazo[1,3,5,) triazinonas y su uso.
DE10010067A1 (de) * 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
US20020006926A1 (en) 2000-04-19 2002-01-17 Roylance H. H. Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
BR0114321A (pt) * 2000-09-29 2003-07-01 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
DE10063108A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
DE10063106A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von 2-(2-Ethoxyphenyl)-substituierten Imidazotriazinonen
DE10064105A1 (de) * 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
MXPA03006936A (es) * 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
DE10107639A1 (de) * 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
DE10108752A1 (de) * 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
WO2002089808A1 (de) * 2001-05-09 2002-11-14 Bayer Healthcare Ag Neue verwendung von 2-phenyl-substituierten imidazotriazinonen
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
GB0113344D0 (en) 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
ATE395349T1 (de) 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
HU228316B1 (en) * 2001-12-13 2013-03-28 Daiichi Sankyo Company Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
GB0209988D0 (en) * 2002-05-01 2002-06-12 Bayer Ag Novel Heterocycles
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2003101276A2 (en) 2002-05-22 2003-12-11 Virginia Commonwealth University Protective effects of pde-5 inhibitors
CA2485984A1 (en) * 2002-05-23 2003-12-04 Pfizer Inc. Pharmaceutical combination of pde5 inhibitors with ace inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
JP2006522127A (ja) 2003-04-01 2006-09-28 スミスクライン ビーチャム コーポレーション イミダゾトリアジン化合物
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20040234916A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
CA2525946C (en) 2003-05-22 2013-01-29 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
CA2562251C (en) * 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
JP2008501617A (ja) * 2004-06-11 2008-01-24 アスビオファーマ株式会社 Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
EP1781360A1 (en) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
EA200701752A1 (ru) * 2005-02-18 2008-04-28 Сурфейс Логикс Инк. Способ получения усовершенствованных фармакокинетических соединений, включающих функциональные остатки или группы, и фармацевтические композиции, содержащие эти соединения
CN102351862A (zh) * 2005-02-18 2012-02-15 表面线段公司 药动学改善的化合物
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
JP2008536888A (ja) 2005-04-19 2008-09-11 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺高血圧症の治療のためのロフルミラスト
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006127368A2 (en) * 2005-05-20 2006-11-30 Lexicon Genetics Incorporated Methods for synthesizing imidazotriazinones
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
JP2009504628A (ja) * 2005-08-10 2009-02-05 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009509984A (ja) 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1984321A1 (en) * 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
AR059517A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7977478B2 (en) * 2006-03-13 2011-07-12 Dr. Reddy's Laboratories Limited Polymorphic forms of vardenafil
US8030356B2 (en) * 2006-03-17 2011-10-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
CN101484411A (zh) 2006-06-27 2009-07-15 桑多斯股份公司 盐的新制备方法
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
ES2548759T3 (es) 2006-08-24 2015-10-20 Surface Logix, Inc. Compuestos farmacocinéticamente mejorados
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
HUE025355T2 (en) 2006-12-12 2016-02-29 Gilead Sciences Inc Composition for treating pulmonary hypertension
CA2677690C (en) 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
CN101674728A (zh) 2007-02-12 2010-03-17 Dmi生物科学公司 降低曲马多的副作用
US20080194529A1 (en) * 2007-02-12 2008-08-14 Auspex Pharmaceuticals, Inc. HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102007027067A1 (de) 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
WO2008151734A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
CN101965348B (zh) * 2007-09-06 2013-11-13 上海特化医药科技有限公司 伐地那非的制备方法及其中间体
PL2228370T3 (pl) 2007-12-28 2012-10-31 Topharman Shanghai Co Ltd N-{1-[3-(2-etoksy-5-(4-etylopiperazynylo)benzenosulfonylo)-4,5-dihydro-5-okso-1,2,4-triazyn-6-yl]etylo}butyroamid, sposób jego wytwarzania i zastosowanie
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
AU2010280358A1 (en) 2009-08-07 2012-03-08 Ranbaxy Laboratories Limited Processes for the preparation of vardenafil
PL2604608T3 (pl) * 2009-11-27 2016-02-29 Adverio Pharma Gmbh Sposób wytwarzania {4,6-diamino-2-[1-(2-fluorobenzylo)-1H-pirazolo[3,4-b]pirydyn-3-ylo]pirymidyn-5-ylo}metylokarbaminianu metylu
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
US8829049B2 (en) 2009-12-21 2014-09-09 Acef S.A. Medicinal composition intended for the treatment of erectile dysfunction in mammals and use of the composition
PL390079A1 (pl) 2009-12-30 2011-07-04 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób otrzymywania wardenafilu i jego izolacji jako soli z kwasem cytrynowym oraz krystaliczna postać tej soli
JP2013523809A (ja) 2010-04-05 2013-06-17 エスケー ケミカルズ カンパニー リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
CN102382129B (zh) * 2010-08-19 2014-02-26 山东轩竹医药科技有限公司 螺环取代的磷酸二酯酶抑制剂
EP2619208B1 (en) 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
PE20131394A1 (es) 2010-09-23 2014-01-11 Abbvie Inc Monohidrato de derivados de aza-adamantano
MX346730B (es) 2010-10-15 2017-03-30 Gilead Sciences Inc Composiciones y metodos para el tratamiento de la hipertension pulmonar.
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
BR112015007731B1 (pt) 2011-10-10 2022-05-31 H. Lundbeck A/S Composto, composição farmacêutica que o compreende e uso do mesmo
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CZ2011767A3 (cs) * 2011-11-24 2013-06-05 Zentiva, K.S. Zpusob prípravy a izolace solí vardenafilu s kyselinami
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
BR112014018199A8 (pt) 2012-01-26 2021-03-02 H Lundbeck As inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
CA2864322C (en) 2012-02-28 2016-08-09 Seoul Pharma. Co., Ltd. High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
CZ307091B6 (cs) 2012-09-14 2018-01-10 Zentiva, K.S. Stabilní farmaceutický přípravek obsahující Vardenafil hydrochlorid
WO2014088326A1 (ko) 2012-12-04 2014-06-12 주식회사 아리바이오 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
MX2015010725A (es) 2013-02-21 2016-05-31 Adverio Pharma Gmbh Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
CN104109164B (zh) * 2013-04-18 2016-05-25 广州朗圣药业有限公司 一种适合工业化的高纯度盐酸伐地那非三水合物的制备方法
US10899756B2 (en) 2013-07-17 2021-01-26 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PL223869B1 (pl) * 2013-12-16 2016-11-30 Starogardzkie Zakłady Farm Polpharma Spółka Akcyjna Sposób otrzymywania wardenafilu i jego soli
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
PT3865484T (pt) 2015-07-07 2024-01-30 H Lundbeck As Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas
SMT202200190T1 (it) 2015-11-16 2022-07-21 Topadur Pharma Ag Derivati del 2-fenil-3,4-diidropirrolo[2,1-f] [1,2,4]triazinone come inibitori della fosfodesterasi e loro usi
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
MX2019013626A (es) 2017-05-22 2020-01-13 Topadur Pharma Ag Modo de accion dual novedoso de activadores de guanilato ciclasa solubles e inhibidores de fosfodiesterasa y usos de los mismos.
CN107445964A (zh) * 2017-07-29 2017-12-08 合肥创新医药技术有限公司 一种盐酸伐地那非杂质的合成方法
MX2020005890A (es) 2017-12-20 2020-10-19 Klaria Pharma Holding Ab Formulacion de pelicula que comprende vardenafil, metodo para su preparacion y uso de la misma.
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
CA3100988A1 (en) 2018-05-25 2019-11-28 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
CN112955967A (zh) 2018-06-14 2021-06-11 阿斯利康(英国)有限公司 用cgmp特异性磷酸二酯酶5抑制剂医药组合物治疗勃起功能障碍的方法
AU2019287549A1 (en) 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
CA3110680A1 (en) 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
BR112021009958A2 (pt) * 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos
ES3040728T3 (en) 2019-03-13 2025-11-04 Otsuka Pharma Co Ltd Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
WO2022123310A1 (en) 2020-12-11 2022-06-16 Ildong Pharmaceutical Co., Ltd. Novel compounds as androgen receptor and phosphodiesterase dual inhibitor
CN121851016A (zh) * 2021-04-21 2026-04-14 长春金赛药业有限责任公司 含咪唑稠环类衍生物、其制备方法及其在医药上的应用
CN114085225A (zh) * 2021-06-04 2022-02-25 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
AU2022354094A1 (en) 2021-09-29 2024-02-15 Topadur Pharma Ag Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
EP4486349A1 (en) 2022-03-02 2025-01-08 Topadur Pharma AG Topical compositions and uses therof
CN119855819B (zh) * 2022-10-19 2025-10-28 长春金赛药业有限责任公司 一种nk3r拮抗剂的晶型及其制备方法和应用
JP2026510233A (ja) 2023-02-16 2026-04-02 ユニバーシティー オブ ロチェスター グリンパ－リンパ流出の改善

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26565A (en) * 1859-12-27 Improved register for railroad-cars
DE812845C (de) 1944-12-07 1951-09-06 Georges Lissac Brille
US2705715A (en) 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1051734A (https=) 1963-01-16
GB1042471A (en) 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
US3169129A (en) 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4287673A (en) * 1980-01-11 1981-09-08 Sunbeam Corporation Hair dryer diffuser
DE3166627D1 (en) 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
DK0524180T3 (da) * 1990-04-11 1995-09-04 Upjohn Co Smagsmaskering af ibuprofen ved fluid bedovertrækning
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) * 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5614627A (en) 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
US5374053A (en) * 1994-01-21 1994-12-20 Heidelberger Druckmaschinen Ag Device for changing the transport position of products
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
CA2395558C (en) * 1997-11-12 2007-07-17 Bayer Aktiengesellschaft Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
MXPA02006240A (es) * 1999-12-24 2003-01-28 Bayer Ag Nuevas imidazo[1,3,5,) triazinonas y su uso.
WO2002089808A1 (de) * 2001-05-09 2002-11-14 Bayer Healthcare Ag Neue verwendung von 2-phenyl-substituierten imidazotriazinonen
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel

Also Published As

Publication number Publication date
BR9812785A (pt) 2000-10-10
CA2309332C (en) 2002-12-03
DK1049695T3 (da) 2002-05-13
JP2001522851A (ja) 2001-11-20
WO1999024433A1 (de) 1999-05-20
HK1031730A1 (en) 2001-06-22
CO4980861A1 (es) 2000-11-27
CA2395558A1 (en) 1999-05-20
DK1174431T3 (da) 2012-08-20
ES2172945T3 (es) 2002-10-01
IL163475A (en) 2015-11-30
PE131799A1 (es) 1999-12-30
GB2346877B (en) 2001-12-05
IL135462A0 (en) 2001-05-20
DE19881732C1 (de) 2002-01-31
TW513431B (en) 2002-12-11
CN1278822A (zh) 2001-01-03
EP1049695B1 (de) 2002-02-13
DK200000766A (da) 2000-05-09
EP1049695A1 (de) 2000-11-08
KR100548120B1 (ko) 2006-02-02
US20040067945A1 (en) 2004-04-08
HU228196B1 (en) 2013-01-28
PT1174431E (pt) 2012-07-24
DE59803108D1 (de) 2002-03-21
CH693954A5 (de) 2004-05-14
EE04781B1 (et) 2007-02-15
SI1174431T1 (sl) 2012-09-28
US7704999B2 (en) 2010-04-27
AR013759A1 (es) 2001-01-10
BG104406A (en) 2001-08-31
IN188419B (https=) 2002-09-21
HU227841B1 (en) 2012-05-02
NO20021714L (no) 2000-05-11
AR035972A2 (es) 2004-07-28
BG65257B1 (bg) 2007-10-31
JP3356428B2 (ja) 2002-12-16
PT1049695E (pt) 2002-07-31
NO314940B1 (no) 2003-06-16
SK7092000A3 (en) 2001-03-12
UY25246A1 (es) 2001-08-27
SE0001745L (sv) 2000-05-11
UA46166C2 (uk) 2002-05-15
KR20010031944A (ko) 2001-04-16
NO20002444D0 (no) 2000-05-11
HU230154B1 (hu) 2015-09-28
HN1998000175A (es) 1999-01-08
HRP20000292A2 (en) 2001-04-30
HK1067124A1 (zh) 2005-04-01
IL135462A (en) 2006-04-10
US6566360B1 (en) 2003-05-20
NO20002444L (no) 2000-05-11
SE0001745D0 (sv) 2000-05-11
US20130059844A1 (en) 2013-03-07
FI113772B (fi) 2004-06-15
CN1123573C (zh) 2003-10-08
US20050070541A1 (en) 2005-03-31
US7122540B2 (en) 2006-10-17
NO20021714D0 (no) 2002-04-11
HRP20000292B1 (hr) 2008-09-30
EP1174431A3 (de) 2002-01-30
GB0010974D0 (en) 2000-06-28
LU90561B1 (de) 2000-12-01
HUP0100394A2 (hu) 2001-09-28
ES2194567A1 (es) 2003-11-16
US6362178B1 (en) 2002-03-26
ID25871A (id) 2000-11-09
CN100430396C (zh) 2008-11-05
FI20001086L (fi) 2000-05-09
EE200000291A (et) 2001-06-15
SE522809C2 (sv) 2004-03-09
HUP0100394A3 (en) 2002-05-28
GB2346877A (en) 2000-08-23
CA2309332A1 (en) 1999-05-20
CY1112949T1 (el) 2016-04-13
MY138535A (en) 2009-06-30
KR20040014591A (ko) 2004-02-14
NZ504436A (en) 2001-08-31
ES2194567B1 (es) 2005-03-01
AU1558799A (en) 1999-05-31
US7696206B2 (en) 2010-04-13
CN1508137A (zh) 2004-06-30
EP1174431A2 (de) 2002-01-23
JP2002348290A (ja) 2002-12-04
SI1049695T1 (en) 2002-06-30
PL340400A1 (en) 2001-01-29
EP2295436A1 (de) 2011-03-16
HRP20020585A2 (en) 2005-10-31
DK176852B1 (en) 2009-12-14
UY25671A1 (es) 2000-03-31
ATE213246T1 (de) 2002-02-15
US7314871B2 (en) 2008-01-01
PL194801B1 (pl) 2007-07-31
PL201336B1 (pl) 2009-03-31
BR9816155B1 (pt) 2010-07-27
CA2395558C (en) 2007-07-17
US20110009367A1 (en) 2011-01-13
ES2386420T3 (es) 2012-08-20
US6890922B2 (en) 2005-05-10
CZ20001759A3 (cs) 2000-10-11
EP1174431B1 (de) 2012-05-30
TR200001338T2 (tr) 2000-08-21
DE19881732D2 (de) 2000-08-24
SK287161B6 (sk) 2010-02-08
US20080113972A1 (en) 2008-05-15
CZ301911B6 (cs) 2010-07-28
JP4388729B2 (ja) 2009-12-24
US20100016323A1 (en) 2010-01-21
AU738675B2 (en) 2001-09-20
KR100430355B1 (ko) 2004-05-04
US20060189615A1 (en) 2006-08-24
HRP20020585B1 (hr) 2013-02-28
CU23063A3 (es) 2005-07-19

Similar Documents

Publication Publication Date Title
TWI229081B (en) 2-phenyl-substituted imidazotriazinones
ES2588238T3 (es) Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
ES2269217T3 (es) Compuestos especificos para los receptores a1, a2a y a3 de adenosina y sus usos.
CN108368089B (zh) 一种去泛素化酶抑制剂
ES2202827T3 (es) Pirrolo(2,3-d)pirimidinas y su uso como inhibidores de la tirosina kinasa.
ES2256797T3 (es) Pirazolopirimidinas sustituidas con alquilo.
AU2004290643B2 (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines with PDE-5 inhibiting activity
AU2002366811B2 (en) Pyrimidine A2B selective antagonist compounds, their synthesis and use
MXPA00011889A (es) Composiciones de pirrolo (2,3d) piridina y su uso.
CN103122001A (zh) Polo样激酶抑制剂
PT1699800E (pt) Inibidores de quinase p-38 heterocíclicos bicíclicos
US20040097498A1 (en) Novel imidazotriazinones and the use thereof
CN107428765A (zh) 用作irak抑制剂的哒嗪酮类大环化合物及其用途
PL165775B1 (pl) Sposób wytwarzania nowych aminokarbonylokarbaminianów PL PL PL PL
EP4244218A1 (en) 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer
Jiang et al. Design, synthesis and anti-inflammatory evaluation of novel pyrrolo [2, 3-d] pyrimidin derivatives as potent JAK inhibitors
ES2317209T3 (es) Pirazolo(4,3-) pirimidinas.
MXPA06005824A (es) Pirazolopirimidinas.
CA2891208C (en) Salt and polymorphic forms of (3r,4s)-l-((4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(mtdia)
CA3161134A1 (en) Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds
RU2260593C2 (ru) 2-фенилзамещенные имидазотриазиноны, способ их получения и фармацевтическая композиция на их основе, обладающая свойствами ингибитора фосфодиэстеразы i,ii и v
JP2019510054A (ja) シクロフィリンの阻害のための化合物及びその使用
HK40043591B (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途
CA2976819A1 (en) Benzimidazole compounds as kinase inhibitors
HK1256059B (en) An inhibitor of deubiquitylating enzymes

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent